From MedPage Today:

1. Clinical Focus in MS: Novel Approaches to Progressive Disease. Although the drug development pipeline still contains numerous products intended for patients with relapsing-remitting multiple sclerosis (RRMS), the consensus among clinicians is that relapses can be effectively squelched in nearly all RRMS patients with the dozen or so currently approved therapies.
2. Clinical Focus in Renal Cell Carcinoma: Indolent Disease Tx. A select subset of patients with metastatic renal cell carcinoma (mRCC) can safely remain in observation for a year or longer, avoiding treatment-related toxicity.
3. When Primary Care Is Primarily Caring. When I started my internal medicine residency, I was pretty sure I was going to rock this primary care thing. I knew the drugs for hypertension, the guidelines for diabetes management, and depression management seemed like nothing more than an algorithm.
4. Anti-IL-6 Shows Promise in Lupus. Promising clinical responses were seen among patients with active systemic lupus erythematosus treated with an interleukin (IL)-6 monoclonal antibody.